What are the side effects of Adalat XL (nifedipine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Adalat XL (Nifedipine)

The most common side effect of Adalat XL (nifedipine) is peripheral edema, which is dose-dependent and occurs in 18-29% of patients, followed by headache, flushing, dizziness, and potential reflex tachycardia due to its potent vasodilatory effects. 1

Common Side Effects

Nifedipine, a dihydropyridine calcium channel blocker, causes side effects primarily related to its vasodilatory action:

  • Peripheral edema: Dose-related with frequency of 18% on 30 mg daily, 22% on 60 mg daily, and 29% on 90 mg daily 1
  • Cardiovascular effects:
    • Headache (15% vs 10% on placebo)
    • Flushing (10% vs 3% on placebo)
    • Dizziness (10% vs 4% on placebo)
    • Palpitations and reflex tachycardia 2
  • Gastrointestinal effects:
    • Nausea (4% vs 2% on placebo)
    • Constipation (reported in <3% of patients) 1

Less Common Side Effects

The following side effects occur with an incidence of 3% or less:

  • Musculoskeletal: Leg cramps
  • Respiratory: Epistaxis (nosebleeds), rhinitis
  • Urogenital: Impotence, urinary frequency
  • Dermatologic: Rash 1

Rare but Serious Side Effects

Rare adverse events reported with nifedipine include:

  • Allergic reactions: Anaphylactic reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria
  • Hepatic: Allergenic hepatitis, jaundice
  • Hematologic: Anemia, leukopenia, thrombocytopenia
  • Neurological: Syncope, transient blindness at peak plasma levels, tremor, paranoid syndrome 1

Precautions and Contraindications

Nifedipine should be used with caution or avoided in:

  1. Patients with significantly impaired left ventricular function due to potential negative inotropic effects 3, 4
  2. Patients with atrioventricular conduction abnormalities 4
  3. Patients with heart failure with reduced ejection fraction 4

Drug Interactions

Important interactions to be aware of:

  • Beta-blockers: Nifedipine should not be used without concomitant beta-blocker therapy in certain cardiac conditions, though caution is advised due to potential additive hypotensive effects 3, 4
  • Digoxin: Nifedipine may increase serum digoxin levels, though the clinical significance is uncertain 4, 2
  • Magnesium sulfate: Combination may increase risk of uncontrolled hypotension 4

Monitoring Recommendations

When taking Adalat XL, patients should be monitored for:

  • Blood pressure: Check in both sitting and standing positions to detect orthostatic changes 4
  • Peripheral edema: Particularly in elderly patients 4
  • Cardiovascular status: Watch for signs of hypotension or tachycardia 2

Comparison with Other Calcium Channel Blockers

Nifedipine differs from non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in its side effect profile:

  • Nifedipine: More likely to cause vasodilatory symptoms (headache, flushing, peripheral edema) and reflex tachycardia; minimal effect on cardiac conduction 4, 2
  • Verapamil/Diltiazem: More likely to cause conduction disturbances, bradycardia, and constipation; stronger negative inotropic effects 4, 2

Clinical Pearls

  • Peripheral edema with nifedipine is dose-dependent and may be reduced by combining with ACE inhibitors 4
  • The vasodilatory side effects (headache, flushing) often diminish with continued therapy 2
  • When switching between different formulations of nifedipine (e.g., Adalat CC and Procardia XL), blood pressure, heart rate, and adverse effects should be monitored 2-4 weeks after the exchange 5

References

Research

Side effects of calcium channel blockers.

Hypertension (Dallas, Tex. : 1979), 1988

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Calcium Channel Blockers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.